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Abstract
Background: There is a need to identify rational criteria and set priorities for vaccines. In Thailand, many licensed
vaccines are being considering for introduction into the Expanded Program on Immunization; thus, the government
has to make decisions about which vaccines should be adopted. This study aimed to set priorities for new vaccines
and to facilitate decision analysis.
Methods: We used a best-worst scaling study for rank-ordering of vaccines. The candidate vaccines were determined
by a set of criteria, including burden of disease, target age group, budget impact, side effect, effectiveness, severity of
disease, and cost of vaccine. The criteria were identified from a literature review and by in-depth, open-ended
interviews with experts. The priority-setting model was conducted among three groups of stakeholders, including
policy makers, healthcare professionals and healthcare administrators. The vaccine data were mapped and then
calculated for the probability of selection.
Results: From the candidate vaccines, the probability of hepatitis B vaccine being selected by all respondents
(96.67 %) was ranked first. This was followed, respectively, by pneumococcal conjugate vaccine-13 (95.09 %) and
Haemophilus influenzae type b vaccine (90.87 %). The three groups of stakeholders (policy makers, healthcare
professionals and healthcare administrators) showed the same ranking trends. Most severe disease, high fever rate
and high disease burden showed the highest coefficients for criterion levels being selected by all respondents. This
result can be implied that a vaccine which can prevent most severe disease with high disease burden and has low
safety has a greater chance of being selected by respondents in this study.
Conclusions: The priority setting of vaccines through a multiple-criteria approach could contribute to transparency
and accountability in the decision-making process. This is a step forward in the development of an evidence-based
approach that meets the need of developing country. The methodology is generalizable but its application to
another country would require the criteria as relevant to that country.
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Background
Universal vaccination, also known as Expanded Program
on Immunization (EPI) or national immunization
program (NIP), is generally accepted as a cost-effective
intervention for infectious diseases [1]. The World
Health Organization (WHO) has recommended EPI vac-
cines since 1974 [2]. Now WHO recommends routine
immunizations for all age groups – children, adolescents
and adults—including pneumococcal conjugate vaccine
(PCV-13) as well as vaccines against bacillus Calmette–
Guérin (BCG), hepatitis B (HepB), polio, diphtheria–
tetanus–pertussis (DTP), Haemophilus influenzae type b
(Hib), rotavirus, measles, rubella and human papilloma
virus (HPV) [3, 4]. While new vaccines are available
against other diseases, their implementation into the
EPI in each country is varied [5, 6]. The Advisory Com-
mittee on Immunization Practices (ACIP) or National
Immunization Technical Advisory Groups (NITAG) in
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each country is normally responsible for vaccine selec-
tion; however, selection criteria are not well formulated.
Many frameworks have been proposed to guide priority-
setting for health interventions, but only a few of them are
applicable for vaccines [7, 8]. Vaccines differ in the
strength of supporting evidence, the extent of improving
health, and economic value to various stakeholders. Vac-
cines also have special considerations when assessing their
cost-effectiveness, including herd immunity, quality of life
lost in young children, parental care and productivity lost,
nonfinancial economic burden, uncertainty, eradication
rate, macroeconomics and tiered pricing [9]. Structured
frameworks for vaccine implementation and decision-
making have been established by several working groups
[6, 8, 10–14]. The criteria may vary in different settings
but the contents are likely to have almost the same con-
cerns: for example, disease burden, vaccine characteristics,
economic considerations and social concerns. However,
these frameworks are lacking in standardization and
reproducibility of the evaluation process [8, 12]. The
decision-making process may be ad hoc and require
judgmental skills [7, 15].
The EPI in Thailand was established in 1977 to eradicate
smallpox and to ensure that all children benefit from life-
saving vaccines [16]. The current EPI includes vaccines
that cover ten diseases: tuberculosis, HepB, diphtheria,
tetanus, pertussis, poliomyelitis, measles, mumps, ru-
bella, and Japanese encephalitis (JE). HepB vaccine was
the most recent vaccine to be adopted, in 1992. The
combination of DTP–HepB vaccine could be integrated
into the EPI without any effects on the administration
and coverage of EPI vaccines [17]. Currently, there are
many licensed vaccines that are being considering for
introduction into the EPI: for example, PCV-13, Hib
vaccine, rotavirus vaccine, hepatitis A vaccine, inacti-
vated poliomyelitis vaccine, HPV vaccine and varicella
zoster vaccine. Factors and evidence considered by the
Thai ACIP include policy issues (e.g. public health pri-
ority, disease burden, economic issues, vaccine safety
and efficacy) and programmatic issues (e.g. strength of
the existing EPI and vaccine availability). There is no
specific method for developing recommendations by
the ACIP. In some cases where data are inadequate, the
opinions of ACIP members or other experts are used to
make recommendations [16]. The ACIP members may
need additional information and critique the opinion of
experts until a final consideration is reached.
New vaccine introduction often leads to the financial
and programmatic constraints. Decision makers need to
take multiple criteria into account simultaneously result-
ing in risk of informational overload [15]. Thus, there is a
need for a multiple-criteria approach which is a concept
that allows a trade-off between multiple criteria in a con-
sistent, systematic, and transparent manner [15, 18, 19].
This approach can help identifying the rational criteria for
priority setting, weighing their relative importance and
also rank-ordering of vaccines [20]. A best-worst scaling
(BWS) study on eliciting preferences of new vaccine
adoption in Thailand was conducted in 2013 [21]. The
BWS study is a quantitative approach that determines
the relative importance that respondents assign to vari-
ous criteria. This method is a criteria-based measure
based on the assumption that health interventions, ser-
vices, products, or policies can be described by these
criteria. The BWS method required identification of
relevant criteria (representing topic areas) and levels
(representing criterion variables, such as category or
amount of criteria) for a meaningful study outcome
[22]. Respondents’ valuation depends on the criterion
level [23]. Respondents are asked to identify the best
and the worst (the most/the least preferred or the
most/the least important) choices within a series of dif-
ferent scenarios [24]. Each scenario has a same set of
criteria and the criterion levels vary across scenarios. It
has the ability to estimate the relative importance of all
criteria on a common scale [25, 26]. It is also less cog-
nitive and easy to complete the scenarios [25].
The present report follows up on that BWS study, with
the aim of setting priorities and facilitating the decision
analysis of new vaccines.
Methods
Setting priority of vaccines included three steps: the
BWS study, the assessment of vaccines and the rank-
ordering of vaccines.
BWS study
The criteria and levels were identified from a literature
review and by in-depth, open-ended interviews with 11
experts, including policy makers, healthcare providers,
healthcare professionals, manufacturers, logisticians and
healthcare managers. Seven criteria were identified,
including: 1) burden of disease, 2) target age group of
vaccine, 3) budget impact, 4) side effect of vaccine, 5)
severity of disease, 6) effectiveness and 7) cost of vaccine
(see Additional file 1: Table S1). Each criterion had three
levels, for example, burden of disease had the level of
10,000, 20,000 and 30,000 new cases per 100,000 popula-
tion per year, respectively. Main-effects orthogonal design
was used to design 18 scenarios, the minimum number
necessary to ensure no correlations between the criteria.
Each scenario showed seven criteria with levels which
represented characteristics of a new vaccine. Before
completing the scenario, respondents were informed
that a new vaccine in each scenario was adopted and
asked them to choose the most and the least important
factor of this vaccine. The questionnaire contained 18
scenarios that had to be completed by each respondent.
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There were three groups of respondents: policy makers,
healthcare professionals and healthcare administrators.
Policy makers were defined as being involved with the
ACIP, the committee on the National List of Essential
Medicines, or the National Health Security Board. Health-
care professionals were defined by membership in an
association or royal college of a specific field: for ex-
ample, pediatrics, obstetrics and gynecology, infectious
diseases or preventive medicine. Healthcare practitioners
and researchers were also included. Healthcare adminis-
trators were those having an administrative role at various
levels of the healthcare system: for example, the regional
National Health Security Office, the Provincial Public
Health Office, or community hospitals.
The questionnaires were administered by postal survey.
We also used a snowball technique which the researcher
asked for assistance from existing respondents to help
identify further respondents with a similar trait of interest.
Seventy of 128 questionnaires were completed. Seventy
respondents included 11 policy makers, 26 healthcare
professionals and 33 healthcare administrators. Then a
conditional logistic regression was used to determine
coefficients for criterion levels and test for their signifi-
cance (see Additional file 1: Table S2).
Assessment of vaccines
We assessed five vaccines, including existing vaccines in
the EPI (JE and HepB) and new vaccines (rotavirus, Hib
and PCV-13). These vaccines were chosen to illustrate a
broad picture of existing vaccines in the EPI and poten-
tial vaccines across different disease areas. A systematic
review was used to summarize evidence and information
of vaccines from all relevant publications. A database
search was used to obtain the data of vaccines on seven
criteria as identified in the BWS study. We conducted a
database search through PubMed, the Cochrane Library,
Ovid and Scopus for local evidence of vaccines. Manual
searches for additional literature were done via Google
and by accessing specific websites of relevant organiza-
tions in the country. Budget impacts of vaccines were
adjusted to 2015 value [27]. Cost of vaccines were
based on the reference prices listed by the Drug and
Medical Supply Information Center, Ministry of Public
Health, in 2015 [28].
Rank-ordering of vaccines
The conditional logistic regression allows the estimation
of twenty-one coefficients for criterion levels relative to
seven criteria. The probability of a vaccine being selected
was calculated based on the coefficients of criterion level
from the logistic regression models (see Equation 1 and
Additional file 1: Table S2):
Logit Pð Þ ¼ ln P= 1‐Pð Þ½  ¼ β1‐3 burden
þ β4‐6age þ β7‐9budget þ β10‐12safety
þ β13‐15severity þ β16‐18effectiveness
þ β19‐21cost þ ε ð1Þ
where P is the probability of a vaccine being selected by
respondents, βi (i = 1–21) are the coefficients of the cri-
terion level indicating the probability of selection (for
example, β1–3 refers to the coefficient of burden-level 1,
the coefficient of burden-level 2 and the coefficient of
burden-level 3, respectively), and ε is a random error
component that varies among scenarios and respon-
dents. The coefficients of criterion level were considered
as weights for priority-setting [7, 29]. These weights re-
lated to the probability of a vaccine being selected by
respondents. Subsequently, the probability of a vaccine
being selected with 95 % confidence interval was calcu-
lated and rank-ordered.
The calculation of the probability of a vaccine being
selected involves several steps. The vaccine data were
identified for the level to fit in each criterion. This iden-
tification is indicated as ‘1’ or ‘0’ to denote criterion
levels of seven criteria. For example, the data of HepB
vaccine was identified as ‘1’ for burden-level 1, ‘0’ as
burden-level 2, ‘0’ as burden-level 3, ‘1’ for age-level 1, ‘0’
for age-level 2, ‘0’ for age-level 3, ‘0’ for budget-level 1, ‘1’
for budget-level 2, ‘0’ for budget-level 3, ‘0’ for safety-
level 1, ‘0’ for safety-level 2, ‘1’ for safety-level 3, ‘0’ for
severity-level 1, ‘0’ for severity-level 2, ‘1’ for severity-
level 3, ‘0’ for effectiveness-level 1, ‘0’ for effectiveness-
level 2, ‘1’ for effectiveness-level 3, ‘0’ for cost-level 1, ‘0’
for cost-level 2 and ‘1’ for cost-level 3. From the regression
model of all respondents, the summation of coefficients
for HepB vaccine would be 1*(−0.6502) + 1*0.3398 +
1*0.0419 + 1*0.8666 + 1*2.0029 + 1*0.3549 + 1*0.4123 =
3.3682. Then the probability of HepB vaccine being
selected by all respondents was calculated as (e3.3682/
(1 + e3.3682))*100 = 96.67 %, where e = 2.71828.
Results
Table 1 shows vaccine data for Thailand, based on seven
criteria developed from the BWS study. All vaccines
were administered to children less than 5 years old.
Rotavirus infection had the highest burden of disease
but lowest severity of disease. PCV-13 had the highest
rate of fever. PCV-13, Hib vaccine and rotavirus vaccine
had high budget impact due to their high prices, whereas
JE vaccine had the lowest budget impact because it is
produced domestically.
Table 2 shows the probability of a vaccine being selected
by respondents and rank-ordering of vaccines by groups.
From the probability of a vaccine being selected by all re-
spondents, HepB vaccine (96.67 %) was ranked first; it was
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followed, respectively, by PCV-13 (95.09 %) and Hib
vaccine (90.87 %). The three groups of stakeholders
(policy makers, healthcare professionals and healthcare
administrators) showed the same ranking trends.
The regression coefficients of criterion level from the
BWS study indicate their relative importance in priority-
setting. Due to the different weight of the coefficients,
most severe disease, high fever rate and high disease
burden showed the highest weight for criterion levels
being selected by all respondents (see Additional file 1:
Table S2). This result can be implied that a vaccine
which can prevent most severe disease with high disease
burden and has low safety has a greater chance of being
selected by respondents in this study.
Discussion
The probability of a vaccine being selected was calculated
from coefficients of criterion levels of seven criteria (see
Equation 1). We considered those coefficients as weights
of the probability. HepB vaccine, the first-ranked vaccine,
had a high probability of being selected due to its high
severity (from hepatocellular carcinoma), high fever rate,
high effectiveness, and targeting of infants. This could
imply that a new vaccine that is able to protect young
children from most severe disease and gain individual
health benefits has a higher opportunity to be ranked as
a high-priority vaccine. These results were in accordance
with other studies that considered burden of disease,
effectiveness, safety and cost-effectiveness as major as-
pects of vaccines [2, 5, 30–32]. However, the impact of
immunization should be evaluated through both nar-
row and broad perspectives. The narrow perspective
will focus on cost savings and short-term productivity
losses [31], whereas the broad perspective will focus on
long-term effects: for example, productivity gains because
of improved cognition and education, and behavioral
changes because of improved physical health and survival.
The broad perspective also includes herd immunity,
equity of health outcomes, financial sustainability and
macroeconomic impact [4, 12, 33, 34].
The BWS results revealed preferences (a liking for
one criterion level over another level in a hypothetical
set of criteria) from three groups of respondents. The
preferences of policy makers reflected the vaccine policy
Table 1 Vaccine data for Thailand, based on seven criteria developed from a best–worst scaling (BWS) study
Criterion Unit Vaccine
JE [27, 28, 37–39] HepBa
[17, 27, 28, 39, 40]
Hib
[27, 28, 39, 41, 42]
Rotavirus
[27, 28, 39, 43, 44]
PCV-13






15–18 6,000–8,000 3.8 33,578 11–29
Target group Age 18–24 months 0–6 months <5 years 0–5 years <5 years
Budget impact Baht per year 239,677,298 355,644,870 1,443,565,660 1,041,994,995 5,121,681,482
Side effect % of fever 1–2 1–6 2–10 0 33
Severity of
disease
n/a Death (10–20 %);
two-thirds of survivors




Death, disability Not severe Invasive
pneumococcal disease
(meningitis, bacteremia)
Effectiveness % 84.8 80 95 70–85 89
Cost of vaccine Baht per course 291 432 1,753 1,265 6,208
Registration year n/a 2002 2000 1998 2008 2010
aThis scenario included HepB vaccine at birth and DTP–HepB vaccine at 2, 4 and 6 months, as recommended in the Thai EPI
JE: Japanese encephalitis; HepB: hepatitis B; Hib: Haemophilus influenzae type B; PCV-13: pneumococcal conjugate vaccine
Table 2 The probability of a vaccine being selected and rank-ordering of vaccines among groups of respondents













1 HepB 91.64 (71.40–97.97) HepB 95.35 (88.70–98.17) HepB 96.05 (88.62–98.70) HepB 96.67 (93.24–98.39)
2 PCV-13 87.24 (60.88–96.78) PCV-13 93.19 (83.99–97.28) PCV-13 94.70 (85.13–98.24) PCV-13 95.09 (90.20–97.60)
3 Hib 78.75 (45.75–94.21) Hib 81.78 (63.22–92.14) Hib 91.75 (78.08–97.20) Hib 90.87 (82.56–95.44)
4 JE 60.29 (25.68–86.96) JE 73.16 (51.08–87.68) JE 59.42 (31.92–82.06) JE 67.80 (50.03–81.59)
5 Rotavirus 33.88 (10.44–69.24) Rotavirus 27.35 (12.60–49.56) Rotavirus 52.89 (26.45–77.81) Rotavirus 33.43 (19.27–51.37)
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of the public health system in a societal perspective. The
preferences of healthcare professionals reflected clinical
practice and self-interest. The preferences of healthcare
administrators reflected a provider perspective for the ad-
ministration and management of vaccines at community,
provincial and regional levels. The rank-ordering of vac-
cines by the three groups showed the same ranking trends
(see Table 2). This could imply that all groups may have
the same policy stances, and thus reflect the underlying
important factor of vaccine adoption for severe disease
with high burden. This alignment was in accordance with
other studies showing that people may give high priority
to a vaccine that protects the population from severe dis-
ease with a high burden, but are concerned about the
budget impact and safety of that vaccine [10–12].
The criteria and levels included in the BWS study
were mapped from a qualitative survey of experts. Cri-
teria from each expert were not the same but were over-
lapping. This was because each expert had different
roles and responsibilities; therefore, his or her concerns
were different. However, there were common interests
among them: for example, budget impact and price of
vaccine were included as the criteria for economic con-
siderations. These criteria were the major concerns of
those experts, which was consistent with other studies
that considered the same concerns [6, 8, 10–14]. There
is no consensus on the number of criteria to include in
the BWS study [35]. Criteria may not always include
every important aspect to every expert [35]. For a mean-
ingful study outcome, it is important to capture domin-
ant criteria to avoid interferences about omitted criteria.
A sufficient wide range of levels should be used to avoid
respondents ignoring some criteria because of little dif-
ference in levels and to make this criterion more salient
to respondents [36]. The suitable number of criteria is
context-specific. We tried to balance between what may
be important to the experts and what was relevant to
the research question and the decision-making context.
The discussion with experts and pilot testing was used
to assess the importance of criteria and refine as few dis-
tinct criteria as possible. Thus well-designed qualitative
study that used good sampling of informants could help
obtaining the full and broader range of concepts and im-
proving the quality of data.
To our knowledge, no other studies have used the
BWS method for rank-ordering of vaccines. Therefore,
we cannot directly compare criteria in the regression
model. However, they may be compared in terms of
components of the criteria. Structured frameworks for
vaccine implementation and decision-making have been
established by several working groups [6, 8, 10–14].
Those frameworks included disease and vaccine char-
acteristics, economic considerations, feasibility of the
program, and qualitative concerns: for example, equity,
politics, and social and legal issues. The analytical
frameworks are useful in the decision-making process,
but only subjectively for prioritization. This study,
however, employed the criteria that are amenable for
quantification, and also provided prioritization of vaccines.
The local evidence on these criteria may also influence
evidence-based decision-making in Thailand.
Limitations
Our study had limitations. First, this study did not in-
clude qualitative concerns in the model, e.g. policy, pol-
itics, equitability, and social concerns. These data can
incorporate difficult or controversial issues that rest
heavily on personal judgment and may potentially have
a large impact on priority-setting. Second, we used a
convenience sample of respondents who were purpos-
ively selected and willing to participate in the BWS
study. This may not represent the target population.
Third, the application of rank-ordering from the same
set of criteria may result in high variation of probability
of a vaccine being selected. Moreover, this BWS study
has been used for the purposes of a student's disserta-
tion. Hence the premise of our study is limited.
Generalizability
The multiple-criteria approach is generalizable to other
settings. However, other countries, with different contexts,
may not have the same preferences of criteria: for example,
cost of vaccine, vaccine safety, and burden of disease.
Then, the criteria may also be different. The prioritization
of vaccines should be done with caution when local evi-
dence is limited or applied in a different context. Further
application of this approach for prioritization of vaccines
in other countries is warranted. More studies are needed
to determine the variation of preferences and criteria for
new vaccine adoption across countries.
Conclusions
This study has demonstrated the application of multiple-
criteria approach in priority setting process. This is a
step forward in the development of an evidence-based
approach to set priorities for vaccines that meets the
need of developing country. The rank-ordering of vac-
cines can contribute to transparency and accountability
in the decision-making process across various diseases.
The methodology is generalizable but its application to
another country would require the criteria as relevant to
that country.
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